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Abstract: A kinetic spectrophotometric method for determination of lisinopril 
in pharmaceuticals has been developed. The method is based on the activator 
action of lisinopril on Cu(II) ions catalysing the oxidation of Nile Blue A with 
hydrogen peroxide in borate buffer (pH 9.3). A decrease of the absorbance was 
recorded at 635 nm after 5 min at 25 °C. Linearity was established by appli-
cation of the tangent method within the concentration range of lisinopril from 
0.8–6.4 μg mL-1, the detection and quantification limits being 0.158 and 0.480 
μg mL-1, respectively. The method was successfully applied to three brands of 
tablets containing lisinopril alone or in combination with hydrochlorothiazide. 
Keywords: lisinopril; Nile Blue A; spectrophotometry; kinetic determination; 
pharmaceuticals. 
INTRODUCTION 
Lisinopril, (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline, belongs 
to the group of angiotensin converting enzyme (ACE) inhibitors, widely applied 
in the treatment of high blood pressure.1 Due to its wide application in medicine, 
there is an increasing interest for the development of sensitive and highly selec-
tive methods for lisinopril determination in pharmaceuticals and biological mate-
rials. Several spectrophotometric2–16 and spectrofluorimetric3,17 procedures have 
been described for lisinopril determination. Thus, zero order5 and derivative 
spectrophotometry2,7–9 have been proposed for the direct determination of lisi-
nopril. Considering the very low absorbance of lisinopril in the UV region, some 
authors have applied derivatisation in order to increase the sensitivity of the de-
termination.3,4,6,10–16 The methods based on derivatisation are time consuming, 
usually require heating and cooling of the reaction mixture and the use of organic 
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solvents. Furthermore, finding out an appropriate reagent that would quantita-
tively react with the analysed substance represents an additional problem of deri-
vatisation. Of all the spectrophotometric methods hitherto proposed for lisinopril 
determination, only Rahman et al.12 recently reported a kinetic procedure.  
The present study was aimed at the development of a rapid and sensitive 
kinetic spectrophotometric method for lisinopril determination in pharmaceuti-
cals. The procedure is based on the activator effect of lisinopril on the oxidation 
reaction of Nile Blue A with hydrogen peroxide, catalysed by Cu(II) ions. The 
method is more sensitive than the already reported spectrophotometric ap-
proaches, which are listed in the literature,15 and lisinopril is determined avoid-
ing derivatisation and the use of organic solvents. 
EXPERIMENTAL 
Apparatus 
A GBC Cintra 20 spectrophotometer (GBC Scientific Equipment Pty Ltd., Dandenog, 
Australia) with 1.0 cm quartz cuvettes and software for kinetic measurements was used. The 
temperature of the samples was maintained at 25±0.1 °C using a Huber Polistat CC2 ther-
mostat.  
Materials and reagents 
Lisinopril dihydrate and hydrochlorothiazide were kindly provided by the Medicines and 
Medical Devices Agency of Serbia (Belgrade, Serbia) and Zdravlje Actavis Company 
(Leskovac, Serbia), respectively. Water content in lisinopril dihydrate standard was deter-
mined by titrimetry at time of use for analysis. Pharmaceutical lisinopril preparations, such as 
Loril® (Srbolek, Serbia), Skopryl® (Alkaloid, Macedonia) and Lizopril® H (Bosnalijek, 
Bosnia and Herzegovina) were purchased from a local market. Claimed lisinopril content per 
tablet in the examined samples was 5 mg lisinopril dihydrate (Loril®), i.e., 10 mg lisinopril 
(Skopryl®) and 10 mg lisinopril dihydrate plus 12.5 mg hydrochlorothiazide (Lizopril® H). 
Nile Blue A (Sigma–Aldrich), hydrogen peroxide 30 % (Merck), disodium tetraborate deca-
hydrate (Baker) and anhydrous copper(II) sulphate (Merck) were of analytical reagent grade. 
Other reagents used throughout the present study were of analytical grade purity. All solutions 
were prepared in double distilled water. The concentrations of the stock solutions were: Nile 
Blue A, 1.00×10-4 mol L-1, and Cu(II) sulphate, 1.00×10-4 mol L-1. Borate buffer (0.1 mol L-1), 
pH 9.3, was prepared by dissolving sodium tetraborate in water. Hydrogen peroxide solution 
(3.92×10-1 mol L-1) was obtained by diluting 30 % H2O2 with water. 
Procedure 
The reaction was performed in a reaction-mixture vessel with three compartments for 
rapid mixing of the stock solutions, designed by L.I. Budarin.18 The measured amounts of 
Nile Blue A and Cu(II) solutions were placed in the first compartment of the vessel, and 
borate buffer, lisinopril solution and water (up to a total volume of 25 mL) in the second 
compartment. After thermostating at 25 °C, hydrogen peroxide solution was added into the 
third compartment and the reaction initiated by mixing the reactants (zero time). After 30 s, 
the absorbance was recorded at 635 nm for 5 min at 30 s intervals. To study the effects of 
hydrochlorothiazide on the determination of lisinopril, a solution of hydrochlorothiazide was 
stored in lisinopril-containing compartment.  
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Calibration curve. A calibration curve was obtained by the described procedure for the 
following amounts of the reagents: 0.8 mL hydrogen peroxide (3.92×10-1 mol L-1), 5 mL 
1.00×10-4 mol L-1 Nile Blue A solution, 4 mL 1.00×10-4 mol L-1 Cu(II) solution, 5 mL borate 
buffer, pH 9.3 (0.1 mol L-1), aliquots of 0.5–4.0 mL of the solution containing 40 μg mL-1 
lisinopril and water up to a total volume of 25 mL.  
Analysis of pharmaceuticals. Twenty lisinopril-containing tablets were precisely 
weighed and pulverised. The amount of the obtained powder corresponding to the mass of a 
single tablet was transferred to a 100 mL volumetric flask and water added up to the volume. 
The mixture was treated for 10 min in an ultrasonic bath and filtered. For further analyses, 0.8 
mL (Skopryl® and Lizopril® H tablets) and 1.6 mL (Loril® tablets) aliquots of the resulting 
filtrates were used. 
RESULTS AND DISCUSSION 
The presence of Cu(II) ions decreased the absorbance in the system Nile 
Blue A – hydrogen peroxide, thus demonstrating that copper ions acted as a 
catalyst of this reaction. Addition of lisinopril to this system led to a further de-
crease of the absorbance, indicating an increased reaction rate and demonstrating 
the activator action of lisinopril. In order to optimise experimental conditions for 
lisinopril determination, the kinetics of the catalytic reaction of the system Nile 
blue A – hydrogen peroxide – Cu(II), in the presence and in the absence of lisi-
nopril, was examined. The reaction rate was recorded spectrophotometrically at 
635 nm, applying the tangent method.18 The concentration ranges of the reagents 
and selected optimal conditions for lisinopril determination are listed in Table I. 
TABLE I. Concentration range and optimal concentrations of the reagents for the deter-
mination of lisinopril by the proposed kinetic spectrophotometric method 
Reagent Range  Optimal  values 
Cu(II), mol L-1 0.40×10-5–2.00×10-5 1.60×10-5 
H2O2, mol L-1 0.625×10-2–1.57×10-2 1.25×10-2 
Borate buffer, pH  8.6–9.3  9.3 
Borate buffer (pH 9.3), mol L-1 1.00×10-2–3.00×10-2 2.00×10-2 
A linear relationship was established within lisinopril concentration range 
0.80–6.40 μg mL–1 (0.197×10–5–1.58×10–5 mol L–1), and the parameters ob-
tained by regression analysis are given in Table II. The precision of the method 
was estimated by performing six determinations of 1.60, 3.20 and 5.60 μg mL–1 
lisinopril. The results obtained are listed in Table III. The accuracy of the method 
was established by performing recovery experiments at three levels (by adding 
80, 100 and 120 % lisinopril of the claimed tablet content) using the standard ad-
dition method. The analysed samples, Skopryl® and Loril® tablets, were spiked 
with additional 8, 10 and 12 mg, i.e., 4, 5 and 6 mg lisinopril, respectively, and 
the content of lisinopril determined by the proposed method. The recoveries 
ranged from 99.16 to 101.4 % (Table IV). 
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The proposed method was applied to the determination of the lisinopril con-
tent in three different commercial tablets (loril, skopryl and lizopril H). 
TABLE II. Statistical data of lisinopril determination by the proposed kinetic spectrophoto-
metric method (n = 6) 
Parameter Value 
Concentration range, μg mL-1 0.80–6.40 
Calibration equation  2.097×10-4 + 1.578×10-5c 
Correlation coefficient (r) 0.9997 
Standard deviation of slope   1.81×10-7 
Standard deviation of intercept  7.57×10-7 
Limit of detection (LOD / μg mL-1) 0.158 
Limit of quantification (LOQ / μg mL-1) 0.480 
TABLE III. Precision test of the proposed kinetic spectrophotometric method for lisinopril 
determination (six independent determinations) 
Analysed lisinopril amount, μg mL-1  SD RSD / %  Standard analytical error 
1.60 0.049  3.15  0.020 
3.20 0.040  1.22  0.016 
5.60 0.028  0.48  0.011 
TABLE IV. Accuracy of the proposed kinetic spectrophotometric method for the deter-
mination of lisinopril (n = 6) 
Pharmaceutical 
formulation 
analyzed 
Amount of lisinopril, mg 
In analysed 
tablets  Standard added Total  SD RSD / % Recovery, % 
Skopryl 9.850  8.00  17.94  0.095  1.17  101.1 
9.850 10.00  19.78  0.127  1.28  99.30 
9.850 12.00  21.75  0.027  0.23  99.16 
Loril   4.544  4.00  8.601  0.088  2.17  101.4 
4.544 5.00  9.522  0.092  1.85  99.56 
4.544 6.00  10.55  0.115  1.91  100.1 
The selectivity of the proposed method was investigated by the determi-
nation of 4 μg mL–1 lisinopril solution in the presence of various water soluble 
compounds commonly found in lisinopril tablets within a relative error of ±5 %. 
The co-existing soluble ingredients did not interfere with the determination (mass 
ratio to lisinopril): Ca2+ (1000); HPO42– (100) and mannitol (10 000). Since lizo-
pril H tablets in addition to lisinopril (10 mg in the form of dihydrate) also con-
tain hydrochlorothiazide (12.5 mg), the effects of the latter component on the de-
termination of lisinopril by the proposed kinetic method were examined. The 
results clearly showed that hydrocholorothiazide did not interfere up to the mass 
ratio lisinopril:hydrochlorothiazide of 1:1.4. Since commercially available phar-
maceutical preparations contain at the most a 1.25 higher content of hydrochloro-
thiazide than lisinopril, the proposed kinetic procedure described in the present 
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work could be successfully applied for the determination of lisinopril in these 
preparations. The obtained results of lisinopril determination in tablets are sum-
marized in Table V. 
TABLE V. Determination of lisinopril in commercial tablets by the proposed kinetic spectro-
photometric method (n = 6) 
Commercial 
tablets 
Claimed content 
per tablet, mg 
Found 
mg 
Found content calculated as 
lisinopril dihydrate, mg 
In relation to 
claimed content, % 
Loril 5a 4.544b 4.947  98.94 
Skopryl   10b 9.850b –  98.50 
Lizopril H  10a 9.286b 10.11  101.1 
aLisinopril dehydrate; 
blisinopril 
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ИЗВОД 
ОДРЕЂИВАЊЕ ЛИЗИНОПРИЛА У ФАРМАЦЕУТСКИМ ПРЕПАРАТИМА ПРИМЕНОМ 
КИНЕТИЧКЕ СПЕКТРОФОТОМЕТРИЈСКЕ МЕТОДЕ 
МИРА ЧАКАР и ГОРДАНА ПОПОВИЋ 
Фармацеутски факултет, Универзитет у Београду, п. пр. 146, Војводе Степе 450, 11000 Београд 
Развијена  је  кинетичка  спектрофотометријска  метода  за  одређивање  лизиноприла  у 
фармацеутским препаратима. Метода се заснива на активаторском дејству лизиноприла на 
реакцију оксидације боје нил плавог-А водоник-пероксидом у боратном пуферу (pH 9,3), а 
која је катализована Cu(II) јонима. Смањење апсорбанције мерено је на 635 nm у временском 
периоду од 5 мин на температури 25 °C. Линеарност је утврђена применом методе тангенса у 
опсегу концентрација лизиноприла 0,8–6,4 μg mL-1, са лимитом детекције 0,158 μg mL-1 и 
лимитом одређивања 0,480 μg mL-1. Метода је примењена за анализу три комерцијална пре-
парата која су садржала лизиноприл и лизиноприл у комбинацији са хидрохлортиазидом. 
(Примљено 31. јануара, ревидирано 23. јула 2012) 
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